Investigation of the Bioavailability of Marine Based Collagen Peptides in Healthy Subjects

The aim of this study is to evaluate the relative bioavailability of different Peptan® Type I collagen peptides in healthy human subjects. The pharmacokinetic parameters AUC0-6h, Cmax and Tmax will be determined from the concentration-time curves of characteristic collagen markers (e.g. hydroxyproline, proline, glycine, di- and tripeptides together with further amino acids) after oral single dose administration.

The following objectives will be evaluated by comparison of pharmacokinetic parameters between the products:

• The impact of different production processes
• The impact of size of collagen peptides
• The impact of different fish sources

Inclusion criteria

• Subject is able and willing to sign the Informed Consent Form prior to screening evaluations
• Age: 18 - 50 years
• Healthy men and women
• BMI: 19 - 28 kg/m2
• Non-smoker

Exclusion criteria

• Relevant history or presence of any severe medical disorder, potentially interfering with this study (e.g. mal absorption, chronic gastro-intestinal diseases, heavy depression, diabetes, acute cancers within last 3 years except basal cell carcinoma of the skin, etc.)
• A significant CVD event within last 3 mo. incl. myocardial infarction, stroke, congestive heart failure
• Significant changes in lifestyle or medication (within last 3 mo.) or surgical intervention or surgical procedure such as bariatric surgery
• For this study clinically relevant abnormal laboratory, ECG, vital signs or physical findings at screening
• Blood donation within 1 month prior to study start or during study
• "Extreme dietary regimes": vegan lifestyle, weight loss diet with <1200 kcal/day for women and <1800 kcal for men
• Intake of anticoagulants like Heparin, Marcumar etc.
• Regular intake of drugs or supplements possibly interfering with this study within 2 weeks prior to study start or during study
• History of hypersensitivity to fish